Leveraging Model Master Files from a Technology Company Perspective: Facilitating Quantitative Medicine in Regulatory...

Area of Science:

• Pharmacometrics and Computational Medicine
• Regulatory Science

Background:

• Computational modeling is increasingly vital for drug development and regulatory submissions.
• Current processes require repetitive submission of validation data, creating inefficiencies.
• Model Master Files (MMFs) are proposed as a solution for managing validated models.

Purpose of the Study:

• To explore the role and potential of Model Master Files (MMFs) in integrating computational modeling into drug development.
• To identify challenges and opportunities associated with MMF implementation for technology providers and regulatory agencies.
• To advocate for enhanced collaboration to maximize MMF benefits in quantitative medicine.

Main Methods:

• Conceptual framework analysis of MMFs in the context of drug development and regulatory science.
• Identification of current challenges in model validation and submission processes.
• Review of intellectual property protection and reuse of validated models.

Main Results:

• MMFs serve as confidential repositories for validated computational models, facilitating streamlined submissions and model reuse.
• Technology companies can leverage MMFs for structured engagement with regulatory bodies like the FDA.
• Key challenges include limited direct FDA interaction and ensuring consistent model validation and version control.

Conclusions:

• MMFs offer a significant advancement for quantitative medicine, enhancing efficiency and collaboration in drug development.
• Addressing challenges through clear guidelines and improved interaction is crucial for widespread MMF adoption.
• Optimizing MMFs will accelerate the use of modeling and simulation, advancing personalized medicine.